CytomX Therapeutics
CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company that develops proteolytically-activated antibodies based on its Probody technology platform. Probody therapeutics are designed to be activated by the tumor microenvironment, enabling targeted cancer immunotherapies with reduced activity in healthy tissues. The company advances antibody and antibody-drug conjugate programs such as CX-072 (PD-L1), CX-2009 (CD166-targeted PDC), BMS-986249 (CTLA-4 Probody), CX-2029 (CD71-targeted PDC), and BMS-986288 (CTLA-4 Probody) in clinical research, and maintains collaborations with AbbVie, Amgen, Bristol-Myers Squibb, ImmunoGen, Pfizer, and Astellas to develop Probody therapeutics. Founded in 2008 and headquartered in South San Francisco, the company aims to improve the precision and safety of antibody-based therapies for cancer and inflammatory diseases.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
1 past transactions
Ardais Corporation
Acquisition in 2005
Ardais Corporation is a clinical genomics company, is dedicated to enhancing and accelerating biomedical research by introducing actual human disease into the pharmaceutical discovery research process. To achieve its goals, Ardais has incorporated multi-disciplinary scientific expertise into its operations, including pathology, molecular biology and genomics, statistical genomics, bioinformatics and medical informatics, as well as process management skills such as logistics, industrial engineering, and robotics. The result of this unique integration is a state-of-the-art, proprietary discovery platform that is dramatically transforming genomic research and leading the way to novel diagnostic and therapeutic solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.